NYSE:AORT Artivion (AORT) Stock Forecast, Price & News $15.45 +0.50 (+3.34%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$14.88▼$15.4650-Day Range$12.39▼$15.4552-Week Range$9.64▼$23.43Volume170,415 shsAverage Volume142,300 shsMarket Capitalization$631.60 millionP/E RatioN/ADividend YieldN/APrice Target$22.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Artivion MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside45.6% Upside$22.50 Price TargetShort InterestBearish7.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.11) to $0.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 starsMedical Sector633rd out of 981 stocksSurgical & Medical Instruments Industry61st out of 97 stocks 3.4 Analyst's Opinion Consensus RatingArtivion has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.50, Artivion has a forecasted upside of 45.6% from its current price of $15.45.Amount of Analyst CoverageArtivion has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.89% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.Change versus previous monthShort interest in Artivion has recently decreased by 0.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AORT. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added Artivion to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Artivion is held by insiders.Percentage Held by Institutions87.99% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Artivion are expected to grow in the coming year, from ($0.11) to $0.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is -21.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is -21.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtivion has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Artivion (NYSE:AORT) StockArtivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.Read More Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Email Address AORT Stock News HeadlinesMay 26, 2023 | americanbankingnews.comArtivion (NYSE:AORT) versus ProSomnus (NASDAQ:OSA) Head-To-Head ComparisonMay 24, 2023 | americanbankingnews.comAnalyzing Artivion (NYSE:AORT) and PAVmed (NASDAQ:PAVM)June 6, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 23, 2023 | markets.businessinsider.comArtivion To Receive Milestone Payment From Baxter On FDA PMA Approval For PerClotMay 23, 2023 | msn.comArtivion wins FDA nod for Baxter-partnered clotting productMay 17, 2023 | americanbankingnews.comCritical Contrast: Artivion (NYSE:AORT) vs. Baxter International (NYSE:BAX)May 8, 2023 | msn.comMorgan Stanley Maintains Artivion (AORT) Equal-Weight RecommendationMay 5, 2023 | msn.comNeedham Maintains Artivion (AORT) Buy RecommendationJune 6, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 4, 2023 | msn.comArtivion: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comArtivion (AORT) Q1 Earnings and Revenues Beat EstimatesMay 4, 2023 | finance.yahoo.comArtivion Reports First Quarter 2023 Financial ResultsMay 4, 2023 | americanbankingnews.comHead-To-Head Contrast: Nyxoah (NASDAQ:NYXH) vs. Artivion (NYSE:AORT)May 3, 2023 | americanbankingnews.comArtivion (AORT) Scheduled to Post Earnings on ThursdayApril 22, 2023 | benzinga.comArtivion Stock (NYSE:AORT), DividendsApril 20, 2023 | finance.yahoo.comArtivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial ResultsApril 20, 2023 | seekingalpha.comArtivion: Reaffirm Hold As Pressures To Growth RemainApril 12, 2023 | americanbankingnews.comArtivion (NYSE:AORT) versus iRhythm Technologies (NASDAQ:IRTC) Financial ContrastApril 10, 2023 | finance.yahoo.comArtivion to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceMarch 31, 2023 | finance.yahoo.comShareholders in Artivion (NYSE:AORT) are in the red if they invested a year agoMarch 6, 2023 | finance.yahoo.comArtivion to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceMarch 2, 2023 | benzinga.comMassive Insider Trade At ArtivionFebruary 18, 2023 | yahoo.comThe Returns On Capital At Artivion (NYSE:AORT) Don't Inspire ConfidenceFebruary 17, 2023 | fool.comWhy Artivion Stock Popped TodayFebruary 17, 2023 | finanznachrichten.deArtivion, Inc.: Artivion Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 16, 2023 | apnews.comArtivion: Q4 Earnings SnapshotFebruary 16, 2023 | msn.comArtivion (AORT) Q4 Earnings Surpass EstimatesSee More Headlines AORT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AORT Company Calendar Last Earnings2/17/2022Today6/06/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:AORT CUSIPN/A CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,300Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.50 High Stock Price Forecast$28.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+47.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,190,000.00 Net Margins-9.17% Pretax Margin-6.71% Return on Equity0.65% Return on Assets0.24% Debt Debt-to-Equity Ratio1.11 Current Ratio5.47 Quick Ratio3.74 Sales & Book Value Annual Sales$313.79 million Price / Sales1.99 Cash Flow$0.61 per share Price / Cash Flow25.16 Book Value$7.05 per share Price / Book2.17Miscellaneous Outstanding Shares40,880,000Free Float38,177,000Market Cap$624.24 million OptionableOptionable Beta1.39 Key ExecutivesJames Patrick MackinChairman, President & Chief Executive OfficerDavid Ashley LeeChief Financial & Operating Officer, EVPScott B. CappsVice President-Clinical ResearchFranz Peter BartholdVice President-Research & DevelopmentMarshall S. StantonChief Medical Officer & SVP-Clinical ResearchKey CompetitorsIRadimedNASDAQ:IRMDMiMedx GroupNASDAQ:MDXGOrthofix MedicalNASDAQ:OFIXOrchestra BioMedNASDAQ:OBIOTactile Systems TechnologyNASDAQ:TCMDView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 67,115 shares on 6/1/2023Ownership: 6.677%Ameriprise Financial Inc.Sold 1,363 shares on 5/22/2023Ownership: 0.596%JPMorgan Chase & Co.Bought 7,851 shares on 5/18/2023Ownership: 0.083%New York State Common Retirement FundSold 10,248 shares on 5/18/2023Ownership: 0.044%Thrivent Financial for LutheransSold 1,400 shares on 5/17/2023Ownership: 0.098%View All Insider TransactionsView All Institutional Transactions AORT Stock - Frequently Asked Questions Should I buy or sell Artivion stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AORT shares. View AORT analyst ratings or view top-rated stocks. What is Artivion's stock price forecast for 2023? 4 brokers have issued twelve-month price objectives for Artivion's stock. Their AORT share price forecasts range from $14.00 to $28.00. On average, they expect the company's stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 47.3% from the stock's current price. View analysts price targets for AORT or view top-rated stocks among Wall Street analysts. How have AORT shares performed in 2023? Artivion's stock was trading at $12.12 at the beginning of 2023. Since then, AORT stock has increased by 26.0% and is now trading at $15.27. View the best growth stocks for 2023 here. When is Artivion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our AORT earnings forecast. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) posted its quarterly earnings results on Thursday, February, 17th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.45. The company had revenue of $79.39 million for the quarter, compared to the consensus estimate of $78 million. Artivion had a negative net margin of 9.17% and a positive trailing twelve-month return on equity of 0.65%. What ETFs hold Artivion's stock? ETFs with the largest weight of Artivion (NYSE:AORT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Inspire Small/Mid Cap ETF (ISMD), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI), What guidance has Artivion issued on next quarter's earnings? Artivion issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $337.00 million-$348.00 million, compared to the consensus revenue estimate of $337.66 million. What is Artivion's stock symbol? Artivion trades on the New York Stock Exchange (NYSE) under the ticker symbol "AORT." Who are Artivion's major shareholders? Artivion's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (17.23%), Macquarie Group Ltd. (6.68%), Macquarie Group Ltd. (6.68%), Wellington Management Group LLP (5.86%), State Street Corp (3.94%) and Dimensional Fund Advisors LP (3.33%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin and Rochelle L Maney. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Artivion's stock price today? One share of AORT stock can currently be purchased for approximately $15.27. How much money does Artivion make? Artivion (NYSE:AORT) has a market capitalization of $624.24 million and generates $313.79 million in revenue each year. The company earns $-19,190,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. How many employees does Artivion have? The company employs 1,300 workers across the globe. How can I contact Artivion? Artivion's mailing address is 1655 Roberts Blvd NW, Kennesaw, Georgia 30144-3632. The official website for the company is www.cryolife.com. The company can be reached via phone at (770) 419-3355, via email at investors@cryolife.com, or via fax at 770-426-0031. This page (NYSE:AORT) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.